Tirzepatide is a newer dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist
Chi Kin WongMcLeanBABaggioLLKoehlerJAHammoudRNikolaj Rittiget al
These events drive aberrant protein aggregation, proteotoxic stress, mitochondrial dysfunction, and energetic collapse, culminating in cell death
As part of our approach, we offer insights into Ozempic, a GLP-1 receptor agonist that helps regulate blood sugar levels and promote weight loss
The distribution of estimated life-years free of new and recurrent CVD events gained with semaglutide was wide, reflecting variation in absolute benefit gained with semaglutide between patients, with those with higher baseline risk and who were younger at treatment initiation experiencing the greatest absolute benefit. Researchers collected data from the SUSTAIN 6 and PIONEER 6 randomized, double-blind, placebo-controlled trials, both of which evaluated the effects of semaglutide (Wegovy, Novo Nordisk) in people with type 2 diabetes at high risk for CVD
